Rheumatoid Arthritis Drugs Market 2034: Clinical Trials, Epidemiology, EMA, PDMA, FDA Approval, Revenue, Statistics, NICE Approvals, Therapies, and Companies by DelveInsight
"Rheumatoid Arthritis Drugs Market"
Rheumatoid Arthritis Companies are Eli Lilly and Company, UCB BIOSCIENCES GmbH, Regeneron/Sanofi, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others.
(Albany, USA) DelveInsight's ' Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market.
Key Takeaways from the Rheumatoid Arthritis Market Report
According to DelveInsight, Rheumatoid Arthritis Market Size in the 7MM was estimated to be around USD 29,000 million in 2023, which is expected to grow during the forecast period (2024–2034).
Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period.
Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023.
In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023.
The leading Rheumatoid Arthritis Companies such as Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others.
Promising Rheumatoid Arthritis Therapies such as Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others.
In February 2025, Inmedix® introduced its CloudHRV™ System to U.S. rheumatologists during the Rheumatology Winter Clinical Symposium held in Wailea, Maui. Cleared for commercialization by the U.S. FDA on January 17, 2025, the CloudHRV System is a heart rate variability (HRV) diagnostic tool intended for clinical use at the discretion of healthcare providers.
In February 2025, Zydus Lifesciences received final approval from the U.S. FDA to manufacture Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This combination therapy is prescribed for the relief of rheumatoid arthritis and osteoarthritis symptoms while also reducing the risk of upper gastrointestinal ulcers associated with long-term ibuprofen use.
In January 2025, Celltrion, a prominent South Korean biopharmaceutical firm, announced U.S. FDA approval for its biosimilar Avtozma. Developed as a biosimilar to Actemra, Avtozma is available in both intravenous and subcutaneous forms and is indicated for autoimmune conditions such as rheumatoid arthritis, giant cell arteritis, and COVID-19.
Additionally, in January 2025, Rise Therapeutics reported that the FDA accepted its Investigational New Drug (IND) application for a Phase 1 oncology trial of R-5780. The company continues to develop treatments targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.
In September 2024, Celltrion announced FDA approval for a Phase 3 clinical study of Zymfentra (CT-P13 SC, infliximab), its subcutaneous Remicade biosimilar, for rheumatoid arthritis treatment.
June 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).
Rheumatoid Arthritis Overview
Rheumatoid Arthritis is a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and potential joint deformity. Rheumatoid Arthritis occurs when the immune system mistakenly attacks the synovium—the lining of the membranes that surround the joints. Rheumatoid Arthritis symptoms typically include joint stiffness, swelling, fatigue, and reduced range of motion, often affecting the wrists, hands, and knees symmetrically.
Rheumatoid Arthritis diagnosis involves a combination of physical examinations, blood tests for inflammatory markers, and imaging techniques such as X-rays or MRIs to assess joint damage. Rheumatoid Arthritis progression can vary widely, with some individuals experiencing mild symptoms and others facing significant disability if left untreated
Rheumatoid Arthritis treatment focuses on controlling inflammation and slowing disease progression through medications such as Disease-Modifying Anti-Rheumatic Drugs (DMARDs), biologics, and corticosteroids. Rheumatoid Arthritis management may also include lifestyle changes, physical therapy, and in severe cases, surgical intervention.
Rheumatoid Arthritis research continues to advance, aiming for more targeted therapies and earlier diagnosis. Rheumatoid Arthritis awareness is essential for early detection and intervention, which can significantly improve long-term outcomes. Rheumatoid Arthritis patients benefit from a multidisciplinary approach involving rheumatologists, physical therapists, and support groups to enhance quality of life and manage daily challenges.
Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Rheumatoid Arthritis Treatment Market
Rheumatoid Arthritis Epidemiology
The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions.
Rheumatoid Arthritis Epidemiology Segmentation:
Total Prevalence of Rheumatoid Arthritis
Prevalent Cases of Rheumatoid Arthritis by severity
Gender-specific Prevalence of Rheumatoid Arthritis
Diagnosed Cases of Episodic and Chronic Rheumatoid Arthritis
Download the report to understand which factors are driving Rheumatoid Arthritis Epidemiology trends @ Rheumatoid Arthritis Prevalence
Rheumatoid Arthritis Marketed Drugs
• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation
OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis
• RINVOQ (upadacitinib): AbbVie
RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.
Rheumatoid Arthritis Emerging Drugs
• Rabeximod (Rob 803): Cyxone
Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors. In June 2022, Cyxone received a response from a Type B pre-IND meeting with the US FDA. The response from the FDA facilitates for Cyxone to continue planning the Phase IIb study with Rabeximod in rheumatoid arthritis.
• Imvotamab: IGM Biosciences
Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells.
Rheumatoid Arthritis Market Outlook
Rheumatoid Arthritis aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA.
Rheumatoid Arthritis Drug Market
The pipeline holds multiple promising therapies in various stages of development, most of which are vaccines. Therapies like Rabeximod (Cyxon), Imvotamab (IGM Biosciences), and others are the drugs and Monoclonal antibodies currently in Phase II and Ib trials focusing on Macrophage inhibition and CD cells depletion, and more may follow in the future. The current pipeline does not hold great potential as most of the products are currently in initial and mid stage trials and most of the drugs failed in their last stage trials as the studies did not meet primary and secondary efficacy endpoints in rheumatoid arthritis treatment. However, Rabeximod by Cyxone is a new drug candidate and unique among marketed drugs as well as drugs in development as it selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis.
Scope of the Rheumatoid Arthritis Market Report
Coverage- 7MM
Rheumatoid Arthritis Companies- Major pharmaceutical and biotechnology companies such as Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sanofi (EPA: SAN), Eli Lilly and Company (NYSE: LLY), UCB BIOSCIENCES GmbH (part of UCB S.A., EBR: UCB), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Changchun GeneScience Pharma (SHE: 000661), Novartis (SWX: NOVN), Istituto Giannina Gaslini, and others.
Rheumatoid Arthritis Therapies- Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others.
Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis Market Drivers and Barriers
Rheumatoid Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Rheumatoid Arthritis Drugs in development @ Rheumatoid Arthritis Clinical Trials Assessment and Pipeline Analysis
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Flow Methodology
6 Rheumatoid Arthritis Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management of Rheumatoid Arthritis
9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology)
10 Treatment Guidelines for RA (National Institute for Health and Care Excellence)
11 Guidelines for Management of RA (American College of Rheumatology)
12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology)
13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR))
14 Treatment Algorithm
15 Epidemiology and Patient Population of 7MM
16 Patient Journey
17 Key Endpoints in Rheumatoid Arthritis Clinical Trials
18 Marketed Drugs
19 Emerging Drugs
20 Rheumatoid arthritis: 7MM Market Analysis
21 Unmet Needs
22 SWOT Analysis
23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies
24 KOL Views
25 Appendix
26 DelveInsight Capabilities
27 Disclaimer
28 About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
8 hours ago
- CBC
Why #SkinnyTok videos are being blocked on TikTok
TikTok has blocked the hashtag #SkinnyTok, following pressure from European officials. According to critics, videos under the hashtag promote disordered eating behaviours disguised as health advice.
Globe and Mail
14 hours ago
- Globe and Mail
B.C. launches $5-million ad campaign to recruit American doctors, nurses
British Columbia has launched a six-week, $5-million campaign of targeted advertisements to recruit doctors and nurses in the United States, citing 'chaos' under the Trump administration to lure them north. The Ministry of Health said the campaign launched on Monday was being shown on thousands of advertising screens in Washington, Oregon and California, at locations within a 16-kilometre radius of health care facilities, as well as on podcasts and Netflix shows. B.C. Health Minister Josie Osborne said at a news conference it was a step B.C. needed to 'take right now' to attract physicians, nurses and other health care workers, and the province would do everything in its power to ease their transition. 'This will help supercharge our overall recruitment campaign to attract U.S. health care workers to B.C.,' she said. Opinion: How to win a trade war Fentanyl czar focused on combatting opioid trade, despite tariff distraction In one of the ads, a disgruntled-looking woman in hospital scrubs listens to 'more news from Washington' before the scene cuts to outdoor views of British Columbia, and listeners are urged to 'follow your heart' to the province. Osborne said the campaign was expected to reach about 250,000 health care workers. She said B.C. was 'taking advantage of the uncertainty and chaos' in the United States after the election of President Donald Trump by reaching out to health workers who shared the values of the province's health care system. One ad says recruits can 'practice evidence-based care' in B.C., while another promises 'universal health care that puts people first.' Looming over these efforts is the question of whether B.C.'s public single-payer system offers sufficient financial incentives. Osborne said it was difficult to directly compare physician salaries in B.C. with those in the United States. 'But I can say that with some of the recent changes we've made, and how we pay family doctors, we know that we have competitive salaries,' she said. 'We also know that we offer very competitive salaries for nursing. We offer some of the highest nursing wages in Canada. We also know, though, that doctors are not just motivated by dollars and cents.' Osborne said nearly 1,600 health care providers had already expressed an interest in moving to B.C. even before the ads launched. These included 700 doctors and 500 nurses, but she could not say how many had made it to B.C. 'We're going to do everything we can to attract as many physicians and nurses as possible,' she said without giving a specific target number. 'Ultimately, the success is measured by what people experience in their communities,' she added. She said B.C. would eventually expand international recruitment to other jurisdictions, likening the process to hitting a target. 'We've got the U.S. right in the centre, the bull's eye, and then right outside in the next rings, are countries like the United Kingdom,' she said. 'That's where we'll be focusing our efforts next.'
CTV News
16 hours ago
- CTV News
B.C. targets U.S. doctors and nurses with recruitment ads near American hospitals
B.C. Minister of Health Josie Osborne in a file photo in Burnaby, B.C., on Monday, June 10, 2024. (Darryl Dyck / The Canadian Press) British Columbia has launched a six-week, $5-million campaign of targeted advertisements to recruit doctors and nurses in the United States. The Ministry of Health says the campaign launched on Monday is being shown on thousands of advertising screens in Washington, Oregon and California, at locations within a 16-kilometre radius of health-care facilities, as well as on podcasts and Netflix shows. B.C. Health Minister Osborne says it's a step B.C. needs to 'take right now' to attract physicians, nurses and other health care workers, and the province will do everything in its power to ease their transition. In one of the ads, a disgruntled-looking woman in hospital scrubs listens to 'news from Washington' before the scene cuts to outdoor views of British Columbia, and listeners are urged to follow their hearts to the province. Osborne says B.C. is 'taking advantage of the certainty and chaos' in the United States after the election of President Donald Trump by reaching out to health workers who share the values of the province's health care system. One ad says recruits can 'practice evidence-based care' in B.C., while another promises 'universal health care that puts people first.' Osborne says nearly 1,600 health-care providers have already expressed an interest in moving to B.C. even before the ads launched, including 700 doctors and 500 nurses, but she could not say how many have made it to B.C. She says B.C. will eventually expand its international recruitment to other jurisdictions, including the United Kingdom. This report by Wolfgang Depner of The Canadian Press was first published June 6, 2025.
